Summary | |
---|---|
Symbol | IL27 |
Name | interleukin 27 |
Aliases | IL27p28; IL-27A; IL27A; MGC71873; IL30; interleukin 30; IL-27AA; IL-27 p28 subunit; IL-27 subunit alpha; IL- ...... |
Chromosomal Location | 16p11 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Secreted Note=Does not seem to be secreted without coexpression of EBI3. |
Domain | - |
Function |
Associates with EBI3 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL27 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of proinflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 has also an effect on cytokine production, it suppresses proinflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T-cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase the expression of MHC class II transactivator/CIITA with resulting up-regulation of major histocompatibility complex class II. IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replication. |
Biological Process |
GO:0001819 positive regulation of cytokine production GO:0002250 adaptive immune response GO:0002263 cell activation involved in immune response GO:0002285 lymphocyte activation involved in immune response GO:0002286 T cell activation involved in immune response GO:0002287 alpha-beta T cell activation involved in immune response GO:0002292 T cell differentiation involved in immune response GO:0002293 alpha-beta T cell differentiation involved in immune response GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response GO:0002366 leukocyte activation involved in immune response GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002521 leukocyte differentiation GO:0002694 regulation of leukocyte activation GO:0002697 regulation of immune effector process GO:0002819 regulation of adaptive immune response GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002825 regulation of T-helper 1 type immune response GO:0002831 regulation of response to biotic stimulus GO:0007159 leukocyte cell-cell adhesion GO:0009615 response to virus GO:0022407 regulation of cell-cell adhesion GO:0030098 lymphocyte differentiation GO:0030217 T cell differentiation GO:0032609 interferon-gamma production GO:0032649 regulation of interferon-gamma production GO:0032729 positive regulation of interferon-gamma production GO:0032943 mononuclear cell proliferation GO:0032944 regulation of mononuclear cell proliferation GO:0035710 CD4-positive, alpha-beta T cell activation GO:0042035 regulation of cytokine biosynthetic process GO:0042088 T-helper 1 type immune response GO:0042089 cytokine biosynthetic process GO:0042093 T-helper cell differentiation GO:0042095 interferon-gamma biosynthetic process GO:0042098 T cell proliferation GO:0042107 cytokine metabolic process GO:0042108 positive regulation of cytokine biosynthetic process GO:0042110 T cell activation GO:0042129 regulation of T cell proliferation GO:0043367 CD4-positive, alpha-beta T cell differentiation GO:0043370 regulation of CD4-positive, alpha-beta T cell differentiation GO:0043900 regulation of multi-organism process GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism GO:0045063 T-helper 1 cell differentiation GO:0045072 regulation of interferon-gamma biosynthetic process GO:0045078 positive regulation of interferon-gamma biosynthetic process GO:0045580 regulation of T cell differentiation GO:0045619 regulation of lymphocyte differentiation GO:0045622 regulation of T-helper cell differentiation GO:0045625 regulation of T-helper 1 cell differentiation GO:0046631 alpha-beta T cell activation GO:0046632 alpha-beta T cell differentiation GO:0046634 regulation of alpha-beta T cell activation GO:0046637 regulation of alpha-beta T cell differentiation GO:0046651 lymphocyte proliferation GO:0050670 regulation of lymphocyte proliferation GO:0050688 regulation of defense response to virus GO:0050792 regulation of viral process GO:0050863 regulation of T cell activation GO:0050865 regulation of cell activation GO:0051249 regulation of lymphocyte activation GO:0051607 defense response to virus GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070661 leukocyte proliferation GO:0070663 regulation of leukocyte proliferation GO:0071593 lymphocyte aggregation GO:0098542 defense response to other organism GO:1902105 regulation of leukocyte differentiation GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903706 regulation of hemopoiesis GO:2000514 regulation of CD4-positive, alpha-beta T cell activation |
Molecular Function |
GO:0005125 cytokine activity GO:0005126 cytokine receptor binding GO:0045523 interleukin-27 receptor binding |
Cellular Component | - |
KEGG | - |
Reactome |
R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-6788467: IL-6-type cytokine receptor ligand interactions R-HSA-168256: Immune System R-HSA-6783589: Interleukin-6 family signaling R-HSA-449147: Signaling by Interleukins |
Summary | |
---|---|
Symbol | IL27 |
Name | interleukin 27 |
Aliases | IL27p28; IL-27A; IL27A; MGC71873; IL30; interleukin 30; IL-27AA; IL-27 p28 subunit; IL-27 subunit alpha; IL- ...... |
Chromosomal Location | 16p11 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between IL27 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between IL27 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | IL27 |
Name | interleukin 27 |
Aliases | IL27p28; IL-27A; IL27A; MGC71873; IL30; interleukin 30; IL-27AA; IL-27 p28 subunit; IL-27 subunit alpha; IL- ...... |
Chromosomal Location | 16p11 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of IL27 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | IL27 |
Name | interleukin 27 |
Aliases | IL27p28; IL-27A; IL27A; MGC71873; IL30; interleukin 30; IL-27AA; IL-27 p28 subunit; IL-27 subunit alpha; IL- ...... |
Chromosomal Location | 16p11 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of IL27 in various data sets.
|
Points in the above scatter plot represent the mutation difference of IL27 in various data sets.
|
Summary | |
---|---|
Symbol | IL27 |
Name | interleukin 27 |
Aliases | IL27p28; IL-27A; IL27A; MGC71873; IL30; interleukin 30; IL-27AA; IL-27 p28 subunit; IL-27 subunit alpha; IL- ...... |
Chromosomal Location | 16p11 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IL27. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | IL27 |
Name | interleukin 27 |
Aliases | IL27p28; IL-27A; IL27A; MGC71873; IL30; interleukin 30; IL-27AA; IL-27 p28 subunit; IL-27 subunit alpha; IL- ...... |
Chromosomal Location | 16p11 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IL27. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IL27. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | IL27 |
Name | interleukin 27 |
Aliases | IL27p28; IL-27A; IL27A; MGC71873; IL30; interleukin 30; IL-27AA; IL-27 p28 subunit; IL-27 subunit alpha; IL- ...... |
Chromosomal Location | 16p11 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IL27. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | IL27 |
Name | interleukin 27 |
Aliases | IL27p28; IL-27A; IL27A; MGC71873; IL30; interleukin 30; IL-27AA; IL-27 p28 subunit; IL-27 subunit alpha; IL- ...... |
Chromosomal Location | 16p11 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of IL27 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | IL27 |
Name | interleukin 27 |
Aliases | IL27p28; IL-27A; IL27A; MGC71873; IL30; interleukin 30; IL-27AA; IL-27 p28 subunit; IL-27 subunit alpha; IL- ...... |
Chromosomal Location | 16p11 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between IL27 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | IL27 |
Name | interleukin 27 |
Aliases | IL27p28; IL-27A; IL27A; MGC71873; IL30; interleukin 30; IL-27AA; IL-27 p28 subunit; IL-27 subunit alpha; IL- ...... |
Chromosomal Location | 16p11 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting IL27 collected from DrugBank database. |
There is no record. |